Craig A. Erickson
Children's Hospital Medical Center, Cincinnati · Indiana University School of Medicine - Department of Psychiatry · Indiana University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Craig A. Erickson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:24 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05418049 · Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug ChallengeChildren's Hospital Medical Center, Cincinnati · active not recruiting · Fragile X Syndrome · principal investigator
- N/ANCT04273087 · Characterization of a Clinical Subpopulation With Autism Spectrum DisorderStalicla SA · completed · Autism Spectrum Disorder
- Early Ph1NCT02998151 · Neurophysiological and Acute Pharmacological Studies in FXS PatientsChildren's Hospital Medical Center, Cincinnati · completed · Fragile X Syndrome
- N/ANCT01850459 · Extracellular Signal-Related Kinase Biomarker Development in AutismChildren's Hospital Medical Center, Cincinnati · completed · Autism Spectrum Disorders · principal investigator
- Ph1NCT01813318 · Study of Acamprosate in AutismChildren's Hospital Medical Center, Cincinnati · completed · Autistic Disorder
- Ph2NCT01300923 · Acamprosate in Youth With Fragile X SyndromeIndiana University · completed · Fragile X Syndrome, Autism Spectrum Disorders · principal investigator
- Ph3NCT01086475 · D-Cycloserine and Social Skills Training in Autism Spectrum DisordersIndiana University · completed · Autistic Disorder, Asperger's Disorder, Pervasive Developmental Disorder NOS · principal investigator
- Ph4NCT00895752 · Riluzole in Fragile X SyndromeIndiana University · completed · Fragile X Syndrome · principal investigator
- Ph2NCT00420459 · A Prospective Open-label Study of Aripiprazole in Fragile X SyndromeIndiana University · completed · Fragile X Syndrome · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Leveraging Long-Read Sequencing to Predict Disease Severity in Fragile X SyndromeR21HD118656 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · fiscal years 2026 · $445,500 awarded in 2026Same name and institution; not confirmed by an ID
- Mechanistic and translational medicine studies of brain neurophysiology and phenotypic heterogeneity in fragile X syndromeP50HD118717 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · fiscal years 2025 to 2026 · $1,881,985 awarded in 2026Same name and institution; not confirmed by an ID
- Translational medicine and mechanistic studies of brain neurophysiology in Fragile X SyndromeU54HD104461 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · fiscal years 2020 to 2024 · $1,600,000 awarded in 2024Grant number is on one of their registry trials
- Using Longitudinal Data to Characterize the Natural History of Fragile X Syndrome (FXS) to Improve Services and Outcomes-Component CU01DD001185 · NCBDDD · CINCINNATI CHILDRENS HOSP MED CTR · fiscal years 2016 to 2019 · $99,998 awarded in 2019Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Molecular and synaptic mechanisms of auditory circuit dysfunction in FXS miceU54HD082008 · NICHD · UT SOUTHWESTERN MEDICAL CENTER · PI KIMBERLY M. HUBER · fiscal years 2014 to 2019Named on NCT02998151
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:24 UTC. The ranking covers the 200 most relevant of 29 PubMed records, and a shared surname and initials can bring in a namesake. All 29 on PubMed
- Effects of hyperbaric oxygenation therapy on cerebral metabolism and intracranial pressure in severely brain injured patients.J Neurosurg · 2001121 citationsRCR 3.8
- STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study.J Autism Dev Disord · 201497 citationsRCR 3.4
- A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder.Mol Autism · 201686 citationsRCR 3.8
- Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome.Psychopharmacology (Berl) · 201375 citationsRCR 2.4
- Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.J Child Adolesc Psychopharmacol · 200963 citationsRCR 2.5
- A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders.Mol Autism · 201654 citationsRCR 2.2
- A prospective open-label study of aripiprazole in fragile X syndrome.Psychopharmacology (Berl) · 201151 citationsRCR 1.7
- Open-label riluzole in fragile X syndrome.Brain Res · 201148 citationsRCR 1.4
- 47 citationsRCR 6.0
- Paliperidone for irritability in adolescents and young adults with autistic disorder.Psychopharmacology (Berl) · 201245 citationsRCR 1.7